DK3331910T3 - Monoklonale antistoffer mod humant b-cellemodningsantigen (bcma) - Google Patents

Monoklonale antistoffer mod humant b-cellemodningsantigen (bcma) Download PDF

Info

Publication number
DK3331910T3
DK3331910T3 DK16750150.1T DK16750150T DK3331910T3 DK 3331910 T3 DK3331910 T3 DK 3331910T3 DK 16750150 T DK16750150 T DK 16750150T DK 3331910 T3 DK3331910 T3 DK 3331910T3
Authority
DK
Denmark
Prior art keywords
humant
bcma
antigen
monoclonal antibodies
antibodies against
Prior art date
Application number
DK16750150.1T
Other languages
English (en)
Inventor
Minh Diem Vu
Klaus Strein
Oliver Ast
Camille Delon
Anne Freimoser-Grundschober
Christian Klein
Samuel Moser
Pablo Umana
Lydia Jasmin Duerner
Tina Weinzierl
Marina Bacac
Ekkehard Moessner
Original Assignee
Engmab Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engmab Sarl filed Critical Engmab Sarl
Application granted granted Critical
Publication of DK3331910T3 publication Critical patent/DK3331910T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
DK16750150.1T 2015-08-03 2016-08-03 Monoklonale antistoffer mod humant b-cellemodningsantigen (bcma) DK3331910T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15179549 2015-08-03
PCT/EP2016/068549 WO2017021450A1 (en) 2015-08-03 2016-08-03 Monoclonal antibodies against bcma

Publications (1)

Publication Number Publication Date
DK3331910T3 true DK3331910T3 (da) 2020-03-16

Family

ID=53776451

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16750150.1T DK3331910T3 (da) 2015-08-03 2016-08-03 Monoklonale antistoffer mod humant b-cellemodningsantigen (bcma)

Country Status (30)

Country Link
US (3) US10683369B2 (da)
EP (2) EP3670535A1 (da)
JP (2) JP6682632B2 (da)
KR (1) KR20180042271A (da)
CN (1) CN108350073B (da)
AU (1) AU2016302881B2 (da)
BR (1) BR112018001955B1 (da)
CA (1) CA2992797A1 (da)
CL (3) CL2018000281A1 (da)
CO (1) CO2018001149A2 (da)
CY (1) CY1122804T1 (da)
DK (1) DK3331910T3 (da)
EA (2) EA036975B1 (da)
EC (1) ECSP18007905A (da)
ES (1) ES2777602T3 (da)
HK (1) HK1249114A1 (da)
HR (1) HRP20200390T1 (da)
HU (1) HUE048939T2 (da)
IL (1) IL257233B (da)
LT (1) LT3331910T (da)
MX (2) MX2018001398A (da)
NZ (1) NZ739252A (da)
PL (1) PL3331910T3 (da)
PT (1) PT3331910T (da)
RS (1) RS60030B1 (da)
SA (1) SA518390854B1 (da)
SG (1) SG10202007177XA (da)
SI (1) SI3331910T1 (da)
WO (1) WO2017021450A1 (da)
ZA (1) ZA201800435B (da)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2605390C2 (ru) 2011-08-23 2016-12-20 Рош Гликарт Аг Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
CA2879768A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
HUE047925T2 (hu) 2013-02-26 2020-05-28 Roche Glycart Ag Bispecifikus, T-sejt-aktiváló, CD3- és CEA-specifikus antigénkötõ molekulák
CA2951599A1 (en) 2014-08-04 2016-02-11 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
WO2016055592A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
MX2017006610A (es) 2014-11-20 2017-09-29 Hoffmann La Roche Terapia combinada de moleculas de union a antigeno biespecificas activadoras de celulas t y antagonistas de union de eje de pd-1.
PE20180484A1 (es) 2015-10-02 2018-03-07 Hoffmann La Roche Moleculas biespecificas de union a antigeno activadoras de celulas t
KR20180085740A (ko) 2015-12-09 2018-07-27 에프. 호프만-라 로슈 아게 항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
US20170233484A1 (en) 2016-02-17 2017-08-17 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
PL3433280T3 (pl) 2016-03-22 2023-07-31 F. Hoffmann-La Roche Ag Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy
JP7022123B2 (ja) 2016-09-30 2022-02-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ３に対する二重特異性抗体
MX2019004621A (es) * 2016-11-02 2019-11-28 Engmab Sarl Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
CN110582509A (zh) 2017-01-31 2019-12-17 诺华股份有限公司 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019053613A2 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
US20200254093A1 (en) 2017-09-14 2020-08-13 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
EP3694878A1 (en) 2017-09-14 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
KR102429747B1 (ko) * 2017-10-13 2022-08-05 하푼 테라퓨틱스, 인크. B 세포 성숙화 항원 결합 단백질
US20200339704A1 (en) 2017-10-18 2020-10-29 James E. Bradner Compositions and methods for selective protein degradation
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
TW201925782A (zh) 2017-11-30 2019-07-01 瑞士商諾華公司 靶向bcma之嵌合抗原受體及其用途
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
AU2019214183B2 (en) * 2018-02-01 2022-04-07 Innovent Biologics (Suzhou) Co., Ltd. Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
EA202091974A1 (ru) 2018-02-21 2020-12-08 Селджин Корпорейшн Связывающие bcma антитела и их применение
US20210130483A1 (en) * 2018-03-26 2021-05-06 Sutro Biopharma, Inc. Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
US11952424B2 (en) 2018-03-30 2024-04-09 Merus N.V. Multivalent antibody
JP7293256B2 (ja) * 2018-05-23 2023-06-19 セルジーン コーポレイション 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体
TW202016136A (zh) 2018-06-01 2020-05-01 瑞士商諾華公司 針對ｂｃｍａ之結合分子及其用途
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
BR112021002072A2 (pt) * 2018-08-08 2021-06-01 Dragonfly Therapeutics, Inc. proteínas de ligação multiespecíficas que se ligam a bcma, nkg2d e cd16, e métodos de uso
CN109134665B (zh) * 2018-08-24 2021-06-11 上海先博生物科技有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用
SG11202101825QA (en) 2018-08-31 2021-03-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
CN109503716B (zh) * 2018-10-08 2021-04-27 浙江生研生物科技有限公司 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
WO2020089794A1 (en) 2018-10-31 2020-05-07 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
JP2022506598A (ja) 2018-11-01 2022-01-17 ジュノー セラピューティクス インコーポレイテッド Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体
CN109678961A (zh) * 2019-01-15 2019-04-26 深圳市南科生物工程有限公司 一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用
CA3126087A1 (en) 2019-02-25 2020-09-03 Novartis Ag Mesoporous silica particles compositions for viral delivery
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
WO2020219978A1 (en) 2019-04-25 2020-10-29 Celgene Corporation Bcma/cd3 bispecific trivalent t-cell engaging (tce) antibodies and their use to treat hematological malignancies
CN110229232B (zh) * 2019-06-19 2020-05-19 北京智仁美博生物科技有限公司 双特异性抗体及其用途
AU2020322588A1 (en) * 2019-07-30 2022-02-03 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Anti-BCMA antibody, antigen-binding fragment thereof and medical use thereof
US20220289859A1 (en) 2019-08-06 2022-09-15 Glaxosmithkline Intellectual Property Development Limited Biopharmacuetical Compositions and Related Methods
CN112574308A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
WO2021068761A1 (zh) * 2019-10-10 2021-04-15 苏州亲为药业有限公司 靶向bcma的具有人猴交叉的人源化单克隆抗体
KR20220093141A (ko) * 2019-11-05 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 Bcma 및 cd3에 대한 항체 치료 방법(methods of treatment with antibodies against bcma and cd3)
EP4065158A2 (en) 2019-11-26 2022-10-05 Novartis AG Chimeric antigen receptors binding bcma and cd19 and uses thereof
KR20220110224A (ko) * 2020-01-03 2022-08-05 바이오션, 인코포레이티드 Bcma에 결합하는 항체 및 이의 용도
KR20220012314A (ko) * 2020-01-03 2022-02-03 살루브리스 (청두) 바이오테크 코., 리미티드 Bcma에 결합하는 항체 및 그의 용도
CN111234020B (zh) * 2020-01-23 2020-10-23 和铂医药(苏州)有限公司 一种bcma结合蛋白及其制备方法和应用
CN111171147B (zh) * 2020-02-11 2021-07-20 北京康普美特创新医药科技有限责任公司 一种抗补体c3分子的全人源单克隆抗体及应用
JP2023514224A (ja) * 2020-02-12 2023-04-05 ブリストル－マイヤーズ スクイブ カンパニー 自己免疫障害における抗ｂｃｍａ治療
US20230256017A1 (en) 2020-02-27 2023-08-17 Jennifer Brogdon Methods of making chimeric antigen receptor-expressing cells
CN115397460A (zh) 2020-02-27 2022-11-25 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
US20230172923A1 (en) 2020-04-30 2023-06-08 Bristol-Myers Squibb Company Methods of treating cytokine-related adverse events
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
WO2022035793A1 (en) * 2020-08-10 2022-02-17 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
TW202227124A (zh) 2020-08-21 2022-07-16 瑞士商諾華公司 用於體內產生ｃａｒ表現細胞的組成物和方法
WO2022094245A1 (en) 2020-10-30 2022-05-05 Vor Biopharma, Inc. Compositions and methods for bcma modification
CN112321713B (zh) * 2020-12-31 2021-05-25 北京艺妙神州医药科技有限公司 一种抗bcma的抗体及其应用
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
CA3218362A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
KR20240004659A (ko) 2021-04-30 2024-01-11 셀진 코포레이션 감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
CN117396513A (zh) 2021-05-28 2024-01-12 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的联合疗法
KR20240040786A (ko) 2021-08-03 2024-03-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 생물제약 조성물 및 안정한 동위원소 표지 펩티드 맵핑 방법
CN116745325A (zh) * 2021-08-16 2023-09-12 上海优替济生生物医药有限公司 Bcma靶向抗体、嵌合抗原受体及其应用
CN117858901A (zh) 2021-08-20 2024-04-09 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
WO2023057893A1 (en) 2021-10-05 2023-04-13 Glaxosmithkline Intellectual Property Development Limited Combination therapies for treating cancer
WO2023144702A1 (en) 2022-01-25 2023-08-03 Glaxosmithkline Intellectual Property Development Limited Combination therapy for cancer
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JPH11504901A (ja) 1994-12-30 1999-05-11 プラネット・バイオテクノロジー・インコーポレイテッド 植物における防御タンパク質を含む免疫グロブリンの製造法およびその使用
GB9501079D0 (en) 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2176574T3 (es) 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
CA2288994C (en) 1997-04-30 2011-07-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
DK2270147T4 (da) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
ES2651952T3 (es) 2000-10-06 2018-01-30 Kyowa Hakko Kirin Co., Ltd. Células que producen unas composiciones de anticuerpo
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
DK1419179T3 (da) 2001-08-10 2010-06-21 Univ Aberdeen Antigenbindingsdomæner fra fisk
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
DE60127143T2 (de) 2001-11-14 2007-11-15 Affimed Therapeutics Ag Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
CA2517054C (en) 2003-02-25 2016-05-10 Medinnova As Use of nucleic acids encoding antibody-like molecules for use in medical treatment
EP1651659A4 (en) 2003-08-07 2008-09-17 Epitomics Inc METHOD FOR HUMANIZATION OF MONOCLONAL RABBIT ANTIBODIES
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1751181B1 (en) 2004-06-02 2012-08-15 AdAlta Pty Ltd BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
EA018897B1 (ru) 2005-01-05 2013-11-29 Ф-Стар Биотехнологише Форшунгс- Унд Энтвиклунгсгез.М.Б.Х. Молекулы иммуноглобулина, содержащие модифицированные участки структурных петель, обладающие свойством связывания, и способ их получения
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
WO2006113665A2 (en) 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
US20070111281A1 (en) 2005-05-09 2007-05-17 Glycart Biotechnology Ag Antigen binding molecules having modified Fc regions and altered binding to Fc receptors
AU2006281980A1 (en) 2005-08-15 2007-02-22 Cephalon Australia Pty Ltd Engineered antibodies with new world primate framework regions
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007042261A2 (en) 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
MX2008013057A (es) 2006-04-14 2009-04-07 Trubion Pharmaceuticals Inc Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas.
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
CA2683370C (en) 2007-04-03 2022-12-13 Micromet Ag Cross-species-specific binding domain
EP2155788B1 (en) 2007-04-03 2012-06-27 Micromet AG Cross-species-specific bispecific binders
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
CA2710912A1 (en) 2008-01-15 2009-07-23 F. Hoffmann-La Roche Ag Afucosylated antibodies against ccr5 and their use
CA2718942A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
ES2588155T3 (es) 2008-10-01 2016-10-31 Amgen Research (Munich) Gmbh Anticuerpo biespecífico de cadena sencilla PSMAxCD3 específico entre especies
HRP20160857T4 (hr) 2008-10-01 2022-12-09 Amgen Research (Munich) Gmbh Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
JP5746040B2 (ja) 2008-12-03 2015-07-08 ゲンマブ エー／エス 定常領域の中に改変を有する抗体変種
PT2406284T (pt) * 2009-03-10 2016-09-29 Biogen Ma Inc Anticorpos anti-bcma
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
EP2640750A1 (en) * 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents and methods for treating diseases that correlate with bcma expression
RS57895B1 (sr) 2011-03-29 2019-01-31 Roche Glycart Ag Fc varijante antitela
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
PL3415531T3 (pl) * 2011-05-27 2024-02-26 Glaxo Group Limited Białka wiążące antygen
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP3689383A1 (en) * 2012-04-11 2020-08-05 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
US10077315B2 (en) * 2013-02-05 2018-09-18 Engmab Sàrl Bispecific antibodies against CD3 and BCMA
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
CA2934436A1 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
LT3628687T (lt) 2014-12-12 2021-11-10 2Seventy Bio, Inc. Chimeriniai bcma antigeno receptoriai

Also Published As

Publication number Publication date
JP2020109117A (ja) 2020-07-16
MX2018001398A (es) 2018-05-28
IL257233B (en) 2021-06-30
ECSP18007905A (es) 2018-10-31
MX2020009649A (es) 2020-10-08
US20190352427A1 (en) 2019-11-21
JP6903188B2 (ja) 2021-07-14
BR112018001955B1 (pt) 2021-05-11
CA2992797A1 (en) 2017-02-09
US20230322957A1 (en) 2023-10-12
IL257233A (en) 2018-03-29
CN108350073A (zh) 2018-07-31
WO2017021450A1 (en) 2017-02-09
ES2777602T3 (es) 2020-08-05
CL2020001048A1 (es) 2020-08-28
AU2016302881A1 (en) 2018-02-08
BR112018001955A2 (pt) 2018-09-18
US10683369B2 (en) 2020-06-16
CN108350073B (zh) 2022-03-18
RS60030B1 (sr) 2020-04-30
EA202092435A2 (ru) 2021-02-26
CY1122804T1 (el) 2021-05-05
JP6682632B2 (ja) 2020-04-15
JP2018532766A (ja) 2018-11-08
HRP20200390T1 (hr) 2020-06-12
PL3331910T3 (pl) 2020-05-18
PT3331910T (pt) 2020-03-24
KR20180042271A (ko) 2018-04-25
CL2020002801A1 (es) 2021-02-19
HUE048939T2 (hu) 2020-09-28
SG10202007177XA (en) 2020-09-29
EP3670535A1 (en) 2020-06-24
AU2016302881B2 (en) 2022-09-15
EA202092435A3 (ru) 2021-06-30
CO2018001149A2 (es) 2018-07-10
US20200283545A1 (en) 2020-09-10
SI3331910T1 (sl) 2020-07-31
EA201890441A1 (ru) 2018-07-31
EP3331910B1 (en) 2019-12-11
LT3331910T (lt) 2020-03-25
ZA201800435B (en) 2018-12-19
SA518390854B1 (ar) 2020-12-07
EA036975B1 (ru) 2021-01-21
NZ739252A (en) 2023-12-22
EP3331910A1 (en) 2018-06-13
CL2018000281A1 (es) 2018-11-09
HK1249114A1 (zh) 2018-10-26

Similar Documents

Publication Publication Date Title
DK3331910T3 (da) Monoklonale antistoffer mod humant b-cellemodningsantigen (bcma)
CL2018000370A1 (es) Nuevos anticuerpos anti-pd-1
DK3455257T3 (da) Anti-pd-l1-antistoffer
DK3332006T3 (da) Hidtil ukendte anti-PD-L1-antistoffer
IL255727A (en) Novel anti-pd-l1 antibodies
DK3344654T3 (da) Anti-lag-3-antistoffer
DK3283110T3 (da) Antistoffer rettet mod interleukin-36-receptor (il-36r)
DK3274366T3 (da) Kimær antigenreceptor
DK3411404T3 (da) Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
BR112017002234A2 (pt) anticorpos anti-pd-l1
BR112017001385A2 (pt) anticorpos anti-pd-1
DK3307322T3 (da) Humaniserede anti-cd40-antistoffer og anvendelser deraf
IL247277A0 (en) Monoclonal antibodies against Ebola
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
DK2953972T3 (da) Fremgangsmåde til udvælgelse af antistoffer mod bcma
KR20180085002A (ko) 인간화된 항-cll-1 항체
DK3441086T3 (da) Monoklonalt anti-PD-1-antistof
DK3606961T3 (da) Garp-tgf-beta-antistoffer
MA40901A (fr) Anticorps bispécifiques anti-tnf/anti-il-3
DK3166973T3 (da) Immunstimulerende monoklonale antistoffer mod human interleukin-2
DK3250593T3 (da) Anti-transthyretin-antistoffer
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3
DK3484921T3 (da) Anti-IL-22R antistoffer
DK3209686T3 (da) Monoklonale anti-gpc-1-antistoffer og anvendelser deraf
DK3126391T3 (da) ANTISTOFFER MOD HPA-1a